PharmiWeb Today Story
- Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
NORTH CHICAGO, Ill. and NEW YORK, May 13, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage AbbVie's expertise in psychiatry and Gilgamesh's innovative research platform to discover novel neuroplastogens.
Classic psychedelic compounds provide novel mechanisms to address mental health disorders, and some have shown promising clinical efficacy where other treatments have been ineffective. However, these first-generation compounds may induce profound psychoactive effects, such as hallucinations, necessitating in-office administration and concomitant supportive care.
Next-generation versions known as neuroplastogens target mechanisms that have shown potential to provide significant clinical benefits and are designed to minimize the challenging effects seen with first-generation compounds. These new compounds hold substantial promise for treating a variety of psychiatric conditions, including mood and anxiety disorders. Gilgamesh has leveraged an innovative research platform to successfully identify lead compounds in this novel class of therapeutics.
"Significant unmet need remains for people living with psychiatric disorders and we know that to innovate in this field, we …
Read More...Articles
How AI is Transforming Regulatory Affairs
08-May-2024
Top 6 Pharmaceutical Companies in the UK 2024
30-Apr-2024
What Does a Clinical SAS Programmer Do?
16-Apr-2024
Featured Events
-
Pharmaceutical Manufacturing & Packaging Congress…
28-Jun-2021 - 29-Jun-2021 -
1st International Conference “WE! are the Clinical…
18-Sep-2021 - 18-Sep-2021 -
Reuters Events: Pharma 2021
11-Oct-2021 - 22-Oct-2021 -
UK Clinical Research: A Professional Awareness Upd…
26-Jan-2022 - 27-Jan-2022 -
PM Society: Measuring Patient Engagement: Opening…
12-Oct-2022 - 12-Oct-2022 -
Finding the Value in Strategic Outsourcing Partner…
22-Feb-2023 - 22-Feb-2023
News
-
Bausch Health Announces Updates Related to Norwich…
14-May-2024 -
Sonnet BioTherapeutics Provides Fiscal Year 2024 S…
14-May-2024 -
Protagonist Therapeutics Announces Oral Presentati…
14-May-2024 -
Tenon Medical Reports First Quarter 2024 Financial…
14-May-2024 -
Hamilton Health Box Raises $10 Million in Series A…
14-May-2024 -
Arden Home Health & Hospice Acquires Mid-Delta Hom…
14-May-2024